Thus, ADH‐1, and ADH‐1‐like agents, may increase the delivery of other plasma protein‐bound anti‐cancer drugs to sites of tumor by increasing the permeability of tumor‐associated vasculature, thereby improving tumor response. This evidence concerns the gene ADH1A and neoplasm.